Shield Therapeutics plc (AIM:STX)

Market Cap	59.92M -26.2%
Revenue (ttm)	44.19M +41.3%
Net Income	-7.82M
EPS	-0.01
Shares Out	1.07B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,219,713
Open	5.64
Previous Close	5.70
Day's Range	5.50 - 5.80
52-Week Range	3.70 - 12.50
Beta	1.73
Analysts	Strong Buy
Price Target	16.67 (+192.46%)
Est. Earnings	Nov 20, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 61
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.

Financial numbers in USD

Analyst Summary

According to 3 analysts, the average rating for STX stock is "Strong Buy." The 12-month stock price target is 17p, which is an increase of 192.46% from the latest price.

Price Target

17p

(192.46% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error